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Abstract
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Influenza A viruses causes a variety of illnesses in humans. The most common infection, seasonal
influenza, is usually a mild, self-limited febrile syndrome, but it can be more severe in infants, the
elderly, and immunodeficient persons, in whom it can progress to severe viral pneumonitis or be
complicated by bacterial superinfection, leading to pneumonia and sepsis. Seasonal influenza also
occasionally results in neurologic complications. Rarely, viruses that have spread from wild birds to
domestic poultry can infect humans; such “avian influenza” can range in severity from mild
conjunctivitis through the rapidly lethal disease seen in persons infected with the H5N1 virus that
first emerged in Hong Kong in 1997. To develop effective therapies for this wide range of diseases,
it is essential to have laboratory animal models that replicate the major features of illness in humans.
This review describes models currently in use for elucidating influenza pathogenesis and evaluating
new therapeutic agents.
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I. Introduction
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Influenza A viruses infecting humans are responsible for a gamut of illnesses ranging from
inapparent infections to pneumonia and severe acute respiratory syndrome. The typical
infection one associates with seasonal influenza is a mild, self-limited febrile syndrome. As
with other respiratory viruses, influenza viruses can cause more severe infections in infants,
the elderly, and immunodeficient persons. In those individuals whose immune system is
compromised or not fully developed, influenza-associated disease will often lead to severe
viral pneumonitis or be complicated by bacterial superinfection, leading to pneumonia and
sepsis. Seasonal influenza also occasionally results in neurologic complications. Even in nonpandemic years, more than 40,000 deaths annually are attributable to influenza infections in
the United States (Dushoff et al., 2006). Much more rarely, humans can become infected by
viruses that have spread directly from wild birds to domestic poultry. Such “avian influenza”
can range in severity from mild conjunctivitis through the rapidly lethal disease seen in persons
infected with the recently emerged Southeast Asian H5N1 virus. However, the potential for
such highly virulent, lethal viruses to spread globally, as in the 1918 “Spanish Flu” pandemic,
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has resulted in a tremendous effort to develop vaccines and antiviral drugs to block the spread
of virus and to treat the disease in humans, so as to prevent death.
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The basic virology, clinical syndromes, epidemiology, and approved antiviral drugs for
influenza virus infections are presented in Table 1. Efforts have intensified in recent years to
understand the pathogenesis of the various forms of influenza virus infection and to develop
new treatments (Beigel and Bray, 2008). To develop effective antiviral therapies for this wide
range of diseases, it is essential to have laboratory animal models that replicate the major
features of illness in humans and provide selective, sensitive and reproducible results. Selecting
the appropriate laboratory animal infection is very important in the drug development process.
Some animals, such as pigs and ferrets, are naturally susceptible to infection by influenza
viruses, but some of the other species that have been used for influenza studies are not. For the
latter, the virus requires adaptation before it can replicate in the animal and/or cause disease
(e.g., human seasonal influenza viruses in mice, rats). Once influenza viruses infect an animal,
the virus may cause nonlethal disease or lethal disease. The type of disease that is induced can
be manipulated by the investigator and is dependent on a variety of factors including virus
strain, amount of virus in the inoculum, route of inoculation, time allowed for the disease to
develop and the animal’s immune status.
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This paper reviews animal models currently in use for the study of influenza pathogenesis and
immune responses to influenza virus infections and to assess vaccine and antiviral drug
efficacy. Models that will be reviewed will include: models of benign influenza, typical severe
seasonal influenza and pneumonia, influenza-associated sepsis, models using H5N1 viruses,
models in which acute respiratory distress syndrome (ARDS) is induced, models of influenzaassociated neurologic disease, models for virus transmission studies, immunocompromised
models, and models of host resistance.

II. Seasonal influenza
A. Models of benign influenza

NIH-PA Author Manuscript

Influenza is usually an acute, self-limited respiratory tract infection that begins with the sudden
onset of high fever, followed by inflammation of the upper respiratory tree and trachea, with
coryza, cough, headache, prostration, malaise and other signs and symptoms that persist for
7–10 days (Taubenberger and Morens, 2008). The virus replicates in both the upper and lower
respiratory tract. In experimental infections in healthy volunteers, influenza A viral replication
peaks approximately 48 hours after inoculation into the nasopharynx, declining thereafter, with
usually little or no virus shed after six days. However, viral antigen can still be detected in cells
from the respiratory tract and secretions of infected individuals by enzyme immunoassay for
several days after infectious virus can no longer be recovered (Wright et al, 2007). A summary
of current animal models available for studying benign seasonal influenza is presented in Table
2.
1. Mice
In mice infected with influenza viruses of low pathogenicity, a mild illness occurs with few of
the signs and symptoms that are seen in humans. The major parameters of mild to moderate
disease are weight loss and the detection of virus, primarily in the lungs (Sidwell and Smee,
2004). In such a model, a polymer-bound 6′ sialyl-N-acetyllactosamine was found to ameliorate
weight loss in treated animals (Gambaryan et al., 2005).
2. Ferrets
Less virulent strains of influenza virus cause mild influenza-like symptoms in ferrets that rarely
end in death. For example ferrets infected with A/Aichi/2/68 (H3N2) did not lose weight
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(Svitek et al., 2008). Only mild respiratory disease occurred in Aichi-infected animals with
occasional sneezing and little serous nose exudate expressed. Virus infection elicits a rapid and
strong upregulation of IFNα, IFNγ, and TNFα, while more virulent strains induced significantly
lower levels of IFNα during the first two days after infection. During the first four days after
infection, only IL-8 was detected in samples from animals inoculated with A/Aichi/2/68,
whereas IL-6 expression was associated with the more virulent viruses (Svitek et al., 2008).
The utility of a ferret model in which a benign infection was induced is illustrated by the results
from the following vaccine study. Ferrets immunized with virosome-based intranasal influenza
vaccine consisting of hemagglutinins from influenza A/Beijing/262/95like (H1N1), A/Sydney/
5/97 (H3N2), and influenza B/Harbin/7/94 and then challenged with the A/Sydney/5/97
(H3N2) strain had less viral shedding in nasal secretions and the vaccine elicited a vaccinespecific antibody response (Lambkin et al., 2004). In addition, the vaccine regimen protected
against fever, weight loss, and infiltration of inflammatory cells.
3. Rats
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“True” rat species have been evaluated to determine their suitability as models for influenza
disease and to ascertain whether genetic background impacts their susceptibility to infection.
In one study, Brown Norway (BN), Fischer-344 (F344) and Sprague–Dawley (SD) rats were
challenged with a rat-adapted influenzaA/Port/Chalmers/173 (H3N2) virus (Daniels et al.,
2003). The virus was adapted to rats by 11 successive passages thorough infected lung
homogenate. The F344 and SD rats were most sensitive to the infection, with 100-fold higher
lung virus titers than seen in the BN rats. Alveolar macrophages, lactate dehydrogenase activity,
and total lung protein concentrations (an indicator of pulmonary edema) were higher in the BN
rats. Neutrophil numbers, interleukin 6 levels, and TNFα activity were greatest in the
bronchoalveolar lavage fluids from F344 and SD rats. Nevertheless, the infection was not lethal
and few pathologic abnormalities were noted in the lungs. Although the study provided insights
into factors of importance in protecting the host from influenza virus infections, rat models
probably have not been characterized well enough to be recommended for use in evaluating
anti-influenza therapies.
Recently Alarcon et al. (2007) demonstrated the use of the Brown Norway rat in evaluating
influenza vaccines. Using microneedle technology for i.d. administration of three different
types of influenza vaccines (Fluzone® 2003–2004 formulations and DNA plasmid-based
vaccine) the investigators demonstrated in a rat model, that a whole inactivated virus elicited
antibody responses to the corresponding wild type parent H3N2 and B strains. Animals treated
with multiple doses of DNA plasmid vaccine also responded with antibody response to the
parent strains.
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4. Pigs
Because influenza A viruses frequently adapt to efficient transmission among pigs, these
animals have occasionally been used as a model for testing vaccines (van der Laan et al.,
2008). Signs of illness include fever, loss of appetite, labored breathing and coughing.
However, the animals rarely die from the disease unless virus is directly inoculated into the
trachea, in which case they exhibit signs of pneumonia. Pigs have been found to have low
susceptibility to recently emerged H5N1 strains (Lipatov et al., 2008). To date, the main use
of the pig has been in the development of vaccines against swine influenza (reviewed by van
der Laan et al., 2008).
Problems that may preclude the use of pigs for influenza studies include caging, the
complexities of animal husbandry and waste management. Thus, the recent development of a
model in Ellegaard Göttingen minipigs appears to offer an alternative, if these animals can be
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shown to develop a fulminant pneumonia using a less intrusive route than intratracheal
inoculation. However, as in the case of common pigs, minipigs were not susceptible to infection
with H5N1 strains such as A/chicken/Yamaguchi/7/04 (Isoda et al., 2006). As with normal
pigs one must always be cautious to obtain animals with no previous exposure to influenza
viruses, since minipigs can be hosts for swine influenza A viruses (Hansen et al., 1997).
5. Nonhuman primates
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Because nonhuman primates are much more closely related to humans than small animals
typically used to study influenza, they have been used as models for human disease. In
particular, rhesus macaques have been used to study pathogenesis and evaluate therapeutic and
prophylactic strategies (see Baas et al., 2006 for review). In addition, the suitability of pigtailed
macaques as models of influenza in the context of transcriptional studies has been evaluated
(Baskin et al. 2004). A recent study examined the innate immune response in affected lung
tissue with viral genetic material present (Baas et al., 2006). The authors used histopathological
analysis of lung tissue, immunohistochemistry, viral and host gene expression by microarray
analysis, proteomics, gene expression in circulating blood cells, and quantitative real-time RTPCR to study individual animal responses until the end of the experiment. The infections were
mild, without pneumonia or significant lung pathology. The investigators were able to
demonstrate significant differences in gene expression within regions in influenza virusinduced lesions, based on the presence or absence of viral mRNA, and correlated them with
transcriptional markers of early disease in peripheral white blood cells (Baas et al., 2006).
The use of viruses causing benign infections in macaques has primarily been used for vaccine
studies. For example, Rimmelzwaan et al. (2001) demonstrated that protective immunity
induced by immune stimulating complex (ISCOM)-based vaccines consisting of the membrane
glycoproteins of A/Philippines/2/82 did not protect macaques from a challenge infection with
A/Netherlands/18/94. However, vaccination of monkeys, which had had a prior infection with
an influenza A/Philippines/2/82-like virus with a single dose of ISCOM vaccine, induced longlasting protective antibody immunity against challenge infection with the homologous virus
A/Netherlands/18/94.
B. Models of severe seasonal influenza and pneumonia
Occasionally in healthy individuals, but much more often in the very young, the elderly, and
the immunocompromised, acute seasonal influenza develops into hemorrhagic bronchitis and
viral pneumonia, characterized by dyspnea, hemoptysis, pulmonary edema and cyanosis. Death
can occur within 48 hours after the onset of symptoms. A summary of animal models available
to study such infections is presented in Table 3.
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In cases of severe influenza pneumonia in humans, histological changes in the lungs include
capillary and small vessel thromboses, necrotizing bronchitis and bronchiolitis, interstitial
edema and inflammatory infiltrates, the formation of hyaline membranes in alveoli and alveolar
ducts, varying degrees of acute edema between the alveoli with or without hemorrhaging, and
diffuse alveolar damage. The later stages of the disease are characterized by organizing diffuse
alveolar damage, fibrosis, epithelial regeneration, and squamous metaplasia. If concomitant
bacterial or fungal infection is present, there may be pronounced neutrophil infiltration into
alveolar air spaces, with a lesser degree of alveolar hemorrhage and edema than in primary
influenza pneumonia (Taubenberger and Morens, 2008).
1. Mice
The mouse remains the primary model for evaluating the antiviral therapy of influenza
pneumonia, due to the inexpensiveness of the animals and their caging and the general fidelity
of the illness in mice to the human disease (Sidwell and Smee, 2004). In addition, many reagents
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are available to study the effects of virus replication and treatment on the mouse immune
system. The laboratory mouse can be experimentally infected with both seasonal influenza A
viruses and influenza B viruses, but this usually requires some adaptation by multiple lung
passage. The adapted virus can then infect murine lung cells, probably as a result of amino acid
changes in the surface hemagglutinins that enable it to bind to cell-surface alpha 2,3-linked
sialic acid molecules (Ibricevic et al., 2006). A recent advance in influenza A modeling has
been the finding that the reconstructed 1918 pandemic influenza virus is lethal for mice (Jeffery
et al., 2001; Taubenberger, 2006).
A number of parameters may be used to monitor influenza virus infection in mice, including
change in body weight, decline in arterial oxygen saturation, increase in serum alpha-1-acid
glycoprotein, mean time to death, and lung weight, viral titer and pathology scores (Sidwell
and Smee, 2000). Disease manifestations often depend on the infectivity and challenge dose
of the virus and (for seasonal influenza virus strains) how well the virus has adapted to the
host. If a virus replicates in mice without causing apparent illness, the effects of therapy can
be monitored using parameters such as lung viral titers, increase in lung weight and increase
in 1-acid glycoprotein (1-AG), all of which increase in nonlethally infected mice (Ottolini et
al., 2005; Sidwell and Smee, 2000).
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Most of the histopathological features of influenza viral pneumonia listed above are also seen
in mice, but some signs and symptoms of human influenza are rarely observed. Mice do not
show outward signs of fever and do not have increased rectal temperatures, nor is dyspnea,
cyanosis or hemoptysis easily, if ever detected in mice infected with strains other than the
H5N1 virus. However, as in humans, reduced blood oxygen saturation levels, a measure of
lung function, can be measured in mice, and these levels are dramatically lower as pneumonia
progresses and the mice approach death (Barnard et al., 2007). Weight loss is also a good
marker of disease severity (Sidwell and Smee, 2000). The reader is referred to the following
recent papers that show the utility of the seasonal influenza mouse model for evaluating
vaccines (reviewed by van der Laan et al., 2008; Hagenaars et al., 2008; Hai et al.; 2008) and
antiviral drugs (Dimmock et al., 2008; Gilbert and McLeay, 2008; Reading et al., 2008; Smee
et al., 2008; Wang et al., 2008).
2. Ferrets
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Because influenza-virus-infected ferrets develop many of the typical signs of infection in
humans, including nasal discharge, anorexia, watery eyes, otologic symptoms and fever, they
are now being used as an animal model for influenza-like pneumonia (Sidwell and Smee,
2000; Govorkova et al., 2007; Smee et al., 2008; Svitek et al., 2008). Virus in high titers can
be recovered from the respiratory tract (Smith and Sweet, 1988; Potter et al., 1976). Although
ferrets mimic seasonal influenza A infections in humans, they appear to be less responsive to
infections by influenza B viruses (Pinto et al., 1969).
A limitation of ferret studies is the lack of specific reagents for studying the ferret immune
system, compared with similar resources for mice. However, this issue will probably be
resolved in the near future with the development of reagents such as cross-reactive monoclonal
antibodies (mAb). For example, CD8+ cells in mouse bronchoalveolar lavages from
pneumonic ferrets were identified with mAb to human CD8 (Rutigliano et al., 2008). Caging
can also be a problem, because most animal facilities require that 1–3 ferrets be housed in
rabbit-style cage systems. Proper caging for work with H5N1 influenza virus is at the final
stages of development, but not yet available for use. Access to specific pathogen-free (influenza
virus seronegative) ferrets is also an issue, and will become increasingly so as the demand for
ferret studies grows. Finally, although ferrets are relatively passive in temperament relative to
their mink cousins, they can become fairly aggressive after being exposed to invasive
procedures.
Antiviral Res. Author manuscript; available in PMC 2010 May 1.
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As a result of the studies described above, a number of studies have been done to show the
adequacy of ferrets as models for testing vaccine efficacy (reviewed by van der Laan et al.,
2008; {Huber, 2008 #4356;Parks, 2007 #4357} and the effectiveness of antiviral drug therapy
(Smee et al., 2008; Oxford et al., 2007; Malakhov et al., 2006).
3. Cotton rats
Cotton rats (Sigmodon hispidus) have several advantages over mice and ferrets as a model for
human influenza, including the availability of reagents to study immunological responses.
When compared to mice of any strain, cotton rats appear to have all the innate and adaptive
immune responses seen in humans, such as Mx gene-mediated responses. Viruses isolated from
humans do not have to be adapted to cotton rats to cause disease (Eichelberger, 2007). The
disadvantages of the cotton rat are primarily animal availability and the aggressiveness of
species, regardless of gender.
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The influenza A cotton rat model is a nasal and pulmonary infection in adult inbred cotton rats.
Animals infected intranasally with doses of a recent H3N2 influenza strain had increased
breathing rates accompanied by weight loss and decreased temperature (Ottolini et al., 2005).
Virus replication peaked within 24 h in the lung, with peak titers proportional to the infecting
dose. Although virus was cleared from the lung by day 3, replication persisted in nasal tissues
for 6 days. Pulmonary pathology included early bronchiolar epithelial cell damage, followed
by extensive alveolar and interstitial pneumonia detectable in animals for up to about three
weeks. Cytokine levels were typical of an inflammatory response to a lung infection; their
upregulation appeared to coincide with increased virus replication. Since this model has not
been gained wide acceptance due to the limitations described above, there are a paucity of
papers using cotton rats to vaccine efficacy (Straight et al., 2008) and antiviral efficacy
(Eichelberger et al., 2004; Stertz et al., 2007) against influenza virus infections.
III. Models of influenza-associated sepsis
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Although influenza virus by itself can cause pneumonia, secondary bacterial pneumonia
beginning either during or shortly after recovery from the primary virus infection is much more
common (Speshock et al., 2007). Co-infections with bacteria in seasonal influenza pandemics
have been associated with approximately 25% of all influenza-related deaths (Gupta et al.,
2008). A recent paper concluded “that influenza A virus infection in conjunction with bacterial
infection led to most of the deaths during the 1918–1919 pandemic” (Morens et al., 2008). A
number of animal models have been developed to evaluate the susceptibility of influenzainfected individuals to bacterial superinfections, such as those caused by Neisseria
meningitidis (Alonso et al., 2003) and Streptococcus pneumoniae (Hayashi et al., 2006; Peltola
et al., 2006; Rosseau et al., 2007; Smith et al., 2007) (Table 4). Thus, efforts have been
undertaken to establish animal models to mimic influenza infections complicated by bacterial
infections, primarily pneumonia (McCullers and English, 2008).
Sun and Metzger (2008) recently proposed a mechanism whereby secondary bacterial infection
can occur. They found that interferon-gamma produced in the lungs of mice during T-cell
responses to influenza virus infection inhibited bacterial clearance by alveolar macrophages.
The higher the levels of interferon-gamma, the greater the suppression of phagocytosis, leading
to enhanced susceptibility to secondary pneumococcal infection.
A. Pneumococcal superinfection
The infectious agent most often complicating influenza is Streptococcus pneumoniae. In a
superinfection model, pneumococcal pneumonia after influenza virus infection was established
in six-week old mice using sublethal doses of both microbes (Hayashi et al., 2006). S.
pneumoniae was inoculated intranasally 7 days after exposure to influenza virus and death in
Antiviral Res. Author manuscript; available in PMC 2010 May 1.
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the presence of both agents only began at day 4 post bacterial exposure. The efficacy of several
quinolones against bacteria-induced pneumonia in this model was evaluated, with gatifloxacin
used successfully to treat the pneumococcal infection.
In another model of secondary pneumococcal pneumonia during influenza A virus infection,
the pathology and immunology that led to fatal disease was studied by specifically looking at
cytokine profiles (Smith et al., 2007). Influenza-infected mice challenged with each of 3
serotypes of S. pneumoniae developed a severe, necrotic pneumonia, characterized by
markedly elevated levels of both pro- and anti-inflammatory molecules in the lungs,
accompanied by a massive influx of neutrophils. Death was associated with the development
of pneumonia and lung inflammation, but not with bacteremia. Thus, this model may be used
to delineate factors associated with the pathogenesis of severe mixed lung infections.
B. Meningococcal superinfection
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In the meningococcal superinfection model, BALB/c mice were inoculated intranasally with
a sublethal dose of mouse-adapted influenza A/Scotland/20/74 (H3N2), followed by intranasal
inoculation with Neisseria meningitidis serogroup C (Alonso et al., 2003). Fatal meningococcal
pneumonia and bacteremia were observed in influenza-infected mice superinfected with
bacteria on day 7, but not on day 10. Thus, the investigators were able to model human
meningococcemia with fatal sepsis, and were also able to examine the role of various bacterial
virulence factors leading to sepsis.
C. Secondary bacterial infection in ferrets
A bacterial superinfection model was also established in ferrets, in which influenza more
closely resembles that found in humans (Peltola et al., 2006). The goals of the study were to
better understand the various sequelae of S. pneumoniae infection, including otitis media,
sinusitis, and pneumonia, and to determine if the frequency and character of secondary
pneumococcal infections differed depending on the strain of influenza virus that preceded
bacterial challenge, as has been reported in humans. The viruses studied were A/Taiwan/1/86
(H1N1), the H3N2 viruses A/Sydney/5/97 and A/Fujian/411/02, and influenza B virus B/
Singapore/222/79. In seven-week-old ferrets inoculated intranasally with virus and 5 days later
with S. pneumoniae, all viruses increased bacterial colonization of the nasopharynx. However,
9 of 10 ferrets infected with H3N2 subtype influenza A viruses developed either sinusitis or
otitis media, while only 1 of 11 infected with an H1N1 virus or an influenza B virus did so.
These data support observations in humans that bacterial complication rates are higher during
seasons when H3N2 viruses predominate (Bhat et al., 2005). This animal model could be useful
for further study of the mechanisms that underlie viral-bacterial disease synergism.
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Secondary infection by Staphylococcus aureus has also been evaluated in cotton rats (Braun
et al., 2007). Although S. aureus superinfections are a relatively rare complication of influenza,
the case fatality rate is extremely high. In addition, all three influenza pandemics of the 20th
century included cases of co-infection with S. aureus in healthier and younger patients (Braun
et al., 2007). Therefore, physiologic and pathologic changes in cotton rats infected with both
S. aureus and influenza A/Wuhan/359/95 (H3N2) was evaluated and compared to the
infections in cotton rats with each agent alone. Peribronchiolitis, interstitial pneumonitis as
well as alveolitis were observed. Although pathology scores began to decline in the co-infected
on day 7 p.i., they remained significantly higher than all other infected cohorts. This was true
even in the cohort co-infected with inactivated S. aureus and influenza virus. Co-infection
resulted in higher mortality than infection with either agent alone, and was associated with
more marked hypothermia, lung pathology an enhancement of proinflammatory cytokine
expression in the lungs (Braun et al., 2007). In addition, bacteremia was prolonged and bacterial
lung titers were higher in co-infected cotton rats.

Antiviral Res. Author manuscript; available in PMC 2010 May 1.

Barnard

Page 8

IV. H5N1 avian influenza

NIH-PA Author Manuscript

In contrast to the human-adapted influenza A viruses that cause benign seasonal influenza in
the majority of patients, the recently emerged Southeast Asian H5N1 virus causes acute viral
pneumonia aggravated by ARDS, toxic shock and multiple organ failure in previously healthy,
immunocompetent individuals (Peiris et al., 2007, Beigel, et al., 2005). Its markedly enhanced
virulence for humans appears at least in part to reflect a difference in viral tropism for cells of
the lower respiratory tract, but until recently, those target cells were unknown for both humans
and other mammals (Rimmelzwaan et al., 2006; van Riel et al., 2006). In a recent study (van
Riel et al., 2006), an H5N1 virus was found to preferentially bind to type II pneumocytes,
alveolar macrophages, and nonciliated bronchiolar cells in the lower respiratory tract of cats,
similar to the clinical scenario in humans (Matrosovich et al., 2004). How well various animal
models resemble human disease may thus reflect the difference in distribution of infection in
the respiratory tract. Because the H5N1 virus infects a wide range of mammalian species
without prior adaptation, a number of animal models are available for study (Table 5).
A. Mice
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Isolates of H5N1 virus recovered from human patients can cause lethal disease in BALB/c
mice without prior adaptation (Evseenko et al., 2007; Hatta et al., 2007; Hatta and Kawaoka,
2005; Isoda et al., 2006; Katz et al., 2000b, Gubareva et al., 1998a). Although the infection is
primarily pulmonary, there is strong evidence of systemic spread to solid organs, including the
brain (Gubareva et al., 1998a; Katz et al., 2000a). Most of these viruses cause necrosis in
respiratory epithelium of the nasal cavity (Hatta et al., 2007), trachea (Hatta et al., 2007),
bronchi, and bronchioles (Katz et al., 2000b, Hatta and Kawaoka, 2005) with accompanying
inflammation and accumulation of fibrin and neutrophils (Katz et al., 2000b). The pathology
in the lungs can be characterized as a peribronchial alveolitis with intra-alveolar serofibrinous
exudate, erythrocytes and neutrophils, and increased numbers of alveolar macrophages (Katz
et al., 2000b). Often the infection results in a bronchointerstitial pneumonia and alveolar edema
or in severe cases it may become a diffuse interstitial pneumonia affecting entire lung lobes
(Dybing et al., 2000). Body temperatures usually decrease by four of five degrees and animals
lose at least 20% or more body when they succumb to the effects of the infection.
In another study, a recent H5N1 isolate was shown to promote significantly higher levels of
pro-inflammatory cytokines in whole lungs and primary human macrophages probably
resulting in early and excessive infiltration of macrophages and neutrophils in the lungs of
mice (Perrone et al., 2008). Another study has suggested that in addition to the typical
proinflammatory cytokines, TNF-a may also contribute to the morbidity during H5N1
influenza virus infection (Szretter et al., 2007).
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Because of the severity of H5N1 infections in humans caused by highly pathogenic avian
influenza viruses, numerous vaccine and antiviral efficacy studies have recently been done in
mice. See the following recent references for vaccine studies (reviewed by van der Laan et al.,
2008; Chen et al., 2008; Chen et al., 2009; Hickman et al., 2008; de Vries et al., 2008) and for
antiviral efficacy studies (Barnard et al., 2007; Boltz et al., 2008a; Ilyushina et al., 2008; Zheng
et al., 2008).
B. Ferrets
Two H5N1 viruses isolated in Hong Kong during the 1997 outbreak were found to readily
infect ferrets (Zitzow et al., 2002). Since then, more H5N1 isolates that are highly pathogenic
for birds have been found to replicate in ferret lungs without prior host adaptation. The
infections generally have been characterized by severe lethargy, fever, weight loss, transient
lymphopenia, and virus replication in the upper and lower respiratory tract and in multiple
organs including the brain. More importantly, the illness induced by these agents was more
Antiviral Res. Author manuscript; available in PMC 2010 May 1.
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severe than that induced by recently isolated human H3N2 viruses. The lungs of H5N1-infected
ferrets showed diffuse inflammation of interalveolar septa with infiltrates of mononuclear cells
and intra-alveolar edema, regardless of the time post infection; in contrast to the scattered
infiltrates seen with other influenza A viruses, these changes were observed throughout the
lungs (Maines et al., 2005). Viral antigens were detected in alveolar bronchial cells or
bronchioles in the majority of animals by day 3 post virus exposure. Brain tissues showed
mononuclear cell infiltrates in the meninges, choroid plexus, and brain parenchyma, and viral
antigens were detected in neurons in the same areas.
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In an effort to determine why the H5N1 virus is more virulent for ferrets than seasonal influenza
A isolates, Cameron et al. (2008) analyzed the expression of host innate immune response
genes during the course of lethal infection. The authors found that many interferon response
genes, including IFI44, ISG15 (G1P2), MX2, OAS1, OAS2, STAT1, TAP1, and UBE1L, were
significantly upregulated ferrets infected with the H5N1 virus, in comparison to an H3N2
isolate. CXCL10, a chemoattractant of activated Th1 lymphocytes and natural killer cells, was
also upregulated to a much greater extent in an H5N1 infection than with the H3N2 virus.
CXCL10 and its receptor CXCR3 are thought to play a role in the temporal development of
innate and adaptive immunity in concert with type I and II interferons (Neville et al., 1997).
In support of that hypothesis, Cameron et al. (2008) found that treatment of H5N1-infected
ferrets with AMG487, a CXCR3 antagonist, markedly reduced the severity of symptoms and
delayed death, compared to untreated animals.
Vaccines (reviewed by Subbarao and Luke, 2007; Chen at al. 2008; Lalor et al., 2008;
Mahmood et al., 2008;) and a number antiviral compounds (Malakhov et al., 2006; Govorkova
et al., 2007; Boltz et al., 2008b; Yun et al., 2008) have been tested in ferrets infected with H5N1
viruses very often have verified findings in mice (Malakhov et al., 2006; Govorkova et al.,
2007; Boltz et al., 2008b; Yun et al., 2008).
C. Cats
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Rimmelzwaan et al. (2006) assessed the virulence of a H5N1 virus in cats by infecting them
by intratracheal inoculation or through feeding on virus-infected chicks. Within two days, most
animals developed fever, conjunctivitis, lethargy, and labored breathing. Virus was detected
in the throat, nasal, and rectum, regardless of the original site of infection. The virus spread
systemically and was detected in the respiratory and digestive tracts, liver, kidney, heart, brain,
and lymph nodes. Cellular damage in infected tissues correlated with the detection of viral
proteins. Histopathological examination of the lungs revealed multiple or coalescing foci of
inflammation and necrosis in the bronchioles. The alveolar and bronchiolar lumina were
infiltrated with alveolar macrophages, neutrophils, and erythrocytes, mixed with fibrin, edema
fluid, and cellular debris. More importantly, some alveoli were covered by hyaline membranes,
which are also seen human lungs upon autopsy. Hyaline membrane formation has not been
observed in mice or other animal models. The epithelium of bronchiolar and alveolar walls,
which were moderately thickened, also had evidence of both necrosis and hyperplasia. There
was also edema and moderate accumulation of mononuclear cells around pulmonary artery
branches. Although there has been some work in defining the cat influenza model for evaluating
pathogenesis of H5N1 infections, few if any studies have been published which describe the
suitability of the cat for doing vaccine (Karaca et al., 2005; Vahlenkamp et al., 2008) and
antiviral efficacy studies.
D. Dogs
Dogs can also be infected with the H5N1 avian influenza virus. Because these animals are
often in close contact with both wild and domestic birds and with humans, this raises the
possibility that the virus could adapt to dogs and be transmitted to humans while retaining
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virulence. To date it has been found that dogs are susceptible to experimental infection but are
not capable of transmitting the virus to other mammals (Giese et al., 2008). The disease in dogs
was characterized by the development of conjunctivitis and fever within 2 days after virus
exposure, which resolved with no other adverse events by day 7. Dogs may be useful more as
sentinel for human disease than as a model for human influenza disease (Cleaveland et al.,
2006).
E. Nonhuman primates
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A cynomolgus macaque (Macaca fascicularis) model of H5N1 (A/HongKong/156/97) virus
infection with pneumonia and ARDS has been developed (Kuiken et al., 2003; Rimmelzwaan
et al., 2003). The principal change in the lung was a necrotizing bronchial interstitial
pneumonia, similar to that described for primary human influenza pneumonia. In contrast to
human H5N1 cases, detection of influenza virus antigen was limited to pulmonary tissue and
tonsils. The model was used to evaluate the efficacy of intravenous zanamivir, which has a
longer half-life than oseltamivir (Stittelaar et al., 2008). Drug levels in the epithelial lining
fluids of the lungs were equivalent to those in plasma. Treated macaques had lower gross
pathology scores and less lung pathology than untreated animals. However, there was
considerable variability in viral lung titers and gross pathology within groups of macaques,
and scattering of foci of lung infection from animal to animal, making it difficult to establish
statistically significant differences. The authors pointed out that such variability probably
reflects what happens within the human population. Some vaccine studies with macaques have
also been done (de Vries et al., 2008; Kreijtz et al. 2008; Ruat et al., 2008 among others).
V. Models of ARDS
ARDS is characterized by a localized hyperinflammatory response to an infectious agent in
the lung, resulting in damage to the alveolus–capillary interface (Hammerbeck et al., 2007).
H5N1 virus-infected humans initially present with clinical signs of influenza-like illness, then
develop progressive pneumonia and may eventually die of ARDS (Grose and Chokephaibulkit,
2004). Thus, some research has been done to develop a model of ARDS in H5N1 virus-infected
mice.
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In one ARDS model using 6- to 8-wk-old BALB/c mice inoculated intranasally with influenza
virus A H5N1 (A/Chicken/Hebei/108/2002), the animals developed typical ARDS, with highly
edematous lungs, dramatic increases in lung weights, progressively more hypoxemia and 80%
mortality by day 8 (Xu et al., 2006). Histological examination revealed inflammatory cell
infiltrates in the alveoli with a significant increase in neutrophils, interstitial edema and
hemorrhage. Levels of TNF-a and L-6 in bronchiolar lavage fluids were significantly increased.
The model thus displayed some of the more significant signs and symptoms associated with
ARDS in humans. A summary of current animal models available for studying ARDS in H5N1
influenza is shown in Table 6.
VI. Models of influenza-associated neurologic disease
Because a number of studies have described neurological sequalae from influenza virus
infections, an animal model in which such complications can be studied and treatment can be
tested would be of importance (Mizuguchi et al., 2007; Steininger et al., 2003). A summary of
current animal models available for studying influenza virus-associated neurotropic disease is
presented in Table 7.
A. Seasonal influenza
Mori et al. (2002) have used a highly neurovirulent recombinant R404BP strain of influenza
A (H1N1) virus to test amantadine therapy in mice. Stereotaxic microinjection of virus into
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the olfactory bulb of the animal results in outward spread to neurons in broad areas of the brain
parenchyma, leading to apoptotic neurogeneration and fatal edema, beginning on day eight.
However, amantadine treatment beginning as late as seven days after virus injection protected
the animals. The disadvantage of this clinically relevant model is that only researchers having
stereotaxic microinjection equipment could use it.
A second study in mice used a neurovirulent A/WSN/33 strain of H1N1 influenza A virus
administered intranasally, resulting in infection of olfactory neurons and anterograde axonal
transport to the olfactory bulbs (Aronsson et al., 2003). Using immunodefective mutant mice
to examine how the immune system controls the spread and persistence of the virus, the authors
showed that an absence of T and B cells allowed the infection to spread fully into the brain.
B. H5N1 avian influenza
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In a simplified neurovirulence model, Park et al. (2002) demonstrated that simple intranasal
instillation of influenza A (H5N1) virus isolated from a patient during the 1997 Hong Kong
outbreak could result in the infection of the murine central nervous system. After initial
replication in the respiratory mucosa, the virus apparently traveled through afferent fibers of
the olfactory, vagal, trigeminal, and sympathetic nerves, where it was detected by
immunohistochemical and in situ hybridization. This study demonstrates the feasibility of
using intranasal installation of viruses isolated directly from patients to establish an
encephalitis-like infection, an ideal way for quickly evaluating antiviral inhibitors.
Yun et al. (2008) injected peramivir intramuscularly into ferrets infected intranasally with the
highly neurovirulent A/Vietnam/1203/04 (H5N1) influenza virus and were able to show that
peramavir delivered in this manner ameliorated virus-induced disease by reducing infectious
virus titers in the lungs and brains and promoted survival in ferrets.
VII. Animal models for the study of drug-resistant influenza virus infections
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The potential for influenza viruses to develop resistance to amantadine and rimantadine has
been well established in clinical studies (Monto and Arden, 1992; Hayden and Hay, 1992;
Englund et al., 1998) and in mice (Sidwell and Smee, 2003). By contrast, viruses that have
acquired resistance to zanamivir and oseltamivir generally display a significant reduction in
infectivity in mice, compared to the parent viruses (Gubareva et al., 2000; Herlocher., et al.,
2004; Yen et al., 2005). This reduction in virulence has been evaluated by several means. In
one study, mice were infected in parallel with equal quantities of the parental and the mutant
viruses, and lungs were removed early in the infection (Gubareva et al., 1997). The virus titer
in each was then determined and the titers of the challenge viruses needed to induce a 50%
infection were compared or the amount of virus produced in the lungs by equivalent
concentrations of the viruses was quantified (Tai et al., 1998). Alternatively, using a mouseadapted influenza virus, the relative virulence of the mutant virus was assessed using
parameters such as increased lung weight, lung pathogenesis scores, lung histopathology, and
decreased SaO2% levels of the lungs (Sidwell et al., 1995).
Ferrets have been used extensively to study the infectivity and virulence of influenza virus
mutants resistant to the neuraminidase inhibitors (Blick et al., 1998; Gubareva et al., 1998b;
Barnett et al., 2000). Blick et al. (1998) found that a zanamivir-resistant influenza virus with
an NA and HA mutation was not resistant to zanamivir in ferrets, even though a small decrease
in sensitivity to the drug had been shown in mice, indicating some potential differences in the
two models when studying drug-resistant viruses. A summary of current animal models
available for studying drug-resistant influenza virus infections is presented in Table 8.
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Influenza can be particularly serious in individuals with congenital or acquired
immunodeficiency because of aging, cancer treatment, organ transplantation, or human
immunodeficiency virus infection (Lee and Barton, 2007). It is therefore important to have
models in which to evaluate the effects of chemotherapy on influenza virus infections in
immunosuppressed animals (Table 9).
Cyclophosphamide treatment has been used to immunosuppress mice to assess the efficacy of
a neuraminidase inhibitor (peramivir) in an immunocompromised host (Sidwell et al., 2003).
Cyclophosphamide was injected intraperitoneally at a dose of 100 mg/kg every four days for
varying lengths of time. Peramivir was capable of significantly ameliorating the influenza virus
infection in mice immunosuppressed by short-term or prolonged cyclophosphamide therapy.
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Severe, combined immunodeficient (SCID) mice also provide a model for evaluating antiinfluenza treatments in an immunocompromised host. In a recent study, SCID mice infected
with an influenza A virus and treated with either oral oseltamivir or the experimental compound
A-322278 showed reduced viral replication, limited weight loss and prolonged survival, so
long as the treatments persisted (Sidwell et al., 2003). However, once treatment was
discontinued, the animals had detectable, progressive viral replication with subsequent clinical
decline. More importantly, drug-resistant virus was detected in the chronically infected, drugtreated mice, but not in the placebo-treated animals that died rapidly from infection.
IX. Models of host resistance (immunocompetence after therapy)
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Effective immune clearance of influenza virus requires an immune system that is intact and
functioning normally. Host resistance models have therefore been used to evaluate the effect
of an antiviral treatment on virus clearance, as an indicator of the immunocompetence of an
animal during or after treatment and to test for the immunotoxicity of a particular agent
(Burleson and Burleson, 2007). Mechanistic studies to detect immunotoxicity should include
measuring innate, humoral and cell mediated immune responses, through parameters such as
cytokine and interferon production, macrophage function, and natural killer cell function and
cytotoxic T lymphocyte activity, as well as influenza-specific antibody during or after drug
treatment. For example, the compound 3M-011, a synthetic human TLR7/8 agonist, was
evaluated for antiviral efficacy and immunotoxicity in a rat HR model, which parallel human
influenza infection, both with respect to time course and development of respiratory tract
lesions (Hammerbeck et al., 2007; Burleson and Burleson, 2007). Intranasal (IN)
administration of 3M-011 significantly inhibited H3N2 influenza viral replication in the nasal
cavity when animals were pretreated or therapeutically treated with the compound. Inhibition
correlated closely with induction of type I interferon and to a lesser extent with other cytokines
such as TNF-α, IL-12, and IFN-γ from rat peripheral blood mononuclear cells, and seemed to
have no negative effect on the immune response to infection.
X. Animal models of influenza A virus transmission
To pose a significant threat to humans, a novel influenza A virus must be able to replicate in
the human respiratory tract and be transmitted efficiently from person to person. This is clearly
demonstrated by the recently emerged H5N1 avian influenza virus, which causes rapidly
overwhelming pneumonia, but has only rarely spread from a patient to close contacts. Animal
models have been developed to evaluate the pandemic potential of influenza viruses, especially
for the H5N1 agent. In one recent study, Yen et al. (2007) housed ferrets infected with a
neuraminidase inhibitor resistant recombinant A/Vietnam/1203/04 (H5N1) influenza virus
together with uninfected ferrets and monitored illness, detectable virus shedding lung viral
titers and death. They observed only limited transmission of infection to health contacts, which
correlated with low amounts of virus in respiratory secretions. The authors concluded that
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molecular determinants in addition to a virus’s receptor binding affinity were responsible for
influenza virus transmission among mammalian species (Yen et al., 2007).
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The guinea pig has also been evaluated as a transmission model mammalian host for influenza
virus. Guinea pigs were found to be highly susceptible to infection with the unadapted virus
A/Panama/2007/99 (H3N2) virus, which replicated to high titers in the upper respiratory tract
(Lowen et al., 2006). Although the animals did not sneeze or cough, virus was shed in nasal
washings. In experiments performed at an ambient temperature of 20°C and under low
humidity, virus was transmitted from infected to non-infected guinea pigs housed either in the
same cage, in an adjacent cage, or in a cage placed 91 cm away. Transmission appeared to be
by droplet spread, and was more efficient at lower ambient temperature and humidity.
XI. Conclusion
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As shown in this review, several species of laboratory animals have proved to be very useful
for research on influenza. Mice, particularly the BALB/c strain, are currently intensively
employed for studying pathogenesis, for demonstrating the efficacy of antiviral drugs, and for
preliminary efficacy studies for vaccines. Studies with antiviral agents have shown the
infection in mice to be predictive of efficacy in humans. For example, all of the currently
approved drugs for treating influenza virus infections were first shown to be efficacious in
mice. Although mice are not readily susceptible to newly isolated human seasonal influenza
viruses and require virus adaptation, many highly pathogenic avian influenza strains require
no adaptation and readily infect mice to cause lethal disease. Mice also do not exhibit some of
the clinical symptoms detected in humans such as nasal exudate, fever, sneezing, and coughing.
However, many clinical signs that seem to markers of disease severity can be measured in mice
to study influenza disease, such as saturated oxygen levels, virus lung titers, cytokine levels,
serum and acute phase proteins. In addition, the use of mouse models enable the investigator
to rapidly evaluate the efficacy of antiviral agents and vaccines at relatively lesser costs than
other animal models.
Ferrets are now being widely used to supplement or validate studies in mice, especially for
H5N1 virus studies in order to comply with new FDA “two animal rule”. A tremendous
advantage of ferrets is that these animals display many clinical symptoms of human influenza.
The model also has a similar complexity to that of humans. However, as with the mouse model,
many host factors found associated with humans are missing or have not yet been discovered
in the ferret. The costs of ferrets, space needed for housing, temperament of the animal once
handled experimentally, and the availability of animals without prior exposure to influenza
remain of concern.
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The other animal species that could be used as models have not been sufficiently studied for
their suitability for routine use in studying influenza disease and influenza pathogenesis. In
addition, immune reagents for some of these other species remain yet to be developed. The
availability of some of the species is very limited, and the costs for housing and handling of
some of the larger species are great.
Despite the evidence of the great influenza pandemic of 1918, which brought about the death
of some 50 million people, influenza is often viewed as a “nuisance” disease, for which
adequate countermeasures are already available. However, the recent emergence of the highly
virulent H5N1 avian influenza virus in Southeast Asia has served as a wakeup call, reminding
the medical community that novel influenza A viruses can unexpectedly enter the human
population and that even the currently circulating seasonal strains are responsible for hundreds
of thousands of deaths worldwide each year. Influenza A viruses, far from being benign
respiratory pathogens, are a major public health problem that calls for a serious and sustained
research response. An essential part of that process is the development of laboratory animal
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models of influenza virus infection for the study of pathogenesis and the evaluation of new
drugs and vaccines. As described in this paper, a number of animal models have been
developed, but many gaps remain. Many of the current models remain incompletely
characterized, and none has been employed to its full potential. New and better models are
needed to provide more accurate answers to critical questions in pathogenesis and therapy. It
is hoped that this paper will contribute to the better use of laboratory animal models to combat
the continuing threat of influenza.
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Table 1

Influenza A virus infections: the basics

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Classification and Structure

Influenza viruses are spherical or pleomorphic, single-stranded, negative-sense RNA viruses belonging to the
family Orthomyxoviridae. Influenza A and B viruses contain eight separate ribonucleoprotein (RNP) segments,
while influenza C virus contains seven, each of which encodes 1 or 2 proteins. The internal antigens (M1 and NP
proteins) are the type-specific antigens used to determine if a particular virus is A, B or C, while the external
hemagglutinin (HA) and neuraminidase (NA) are the subtype- and strain-specific antigens.

Infection cycle

Influenza virus binds to receptors on the surface of the host cell via the HA protein. It is internalized into
endosomes, after which pH-dependent fusion and uncoating release the viral RNPs into the cytoplasm, where
they are transported into the nucleus for replication. Viral messenger RNAs are exported out of the nucleus for
protein synthesis, and some of the resulting proteins are transported back into the nucleus to assist in replication
and RNP assembly. New RNPs assemble with other virus proteins at the M1 matrix to form virions, which bud
from the plasma membrane.

Epidemiology

Influenza A viruses cause chronic, asymptomatic infection in the gastrointestinal tracts of wild birds, but are also
able to infect and cause disease in a variety of mammals. Such avian viruses cause a range of illness in humans,
ranging from conjunctivitis through the fulminant illness caused by the recently emerged H5N1 virus. On rare
occasions, an influenza A virus is introduced into human populations and spreads rapidly to cause a global
pandemic. This can occur either when an avian virus with a novel HA protein adapts to human-to-human
transmission, or when an avian virus undergoes genomic reassortment during co-infection of an influenza virusinfected mammal such as a pig. As a pandemic virus circulates, it undergoes progressive antigenic drift in its HA
and NA proteins, permitting to re-infect the same populations in regular outbreaks of “seasonal” influenza.

Clinical syndromes

Symptoms of seasonal influenza typically include high fever, chills, headache, sore throat, dry cough, myalgia,
anorexia, and malaise. Complications include primary viral pneumonia, secondary bacterial pneumonia, or
combined bacterial and viral pneumonia. Severe infections caused by the recently emerged avian influenza A
H5N1 virus are characterized by rapid development of diffuse interstitial pneumonia, viremia and shock leading
to death.

Vaccines

Inactivated vaccines (Fluzone®, Fluvirin™) obtained from infected chicken embryos are most commonly used.
Attenuated vaccines include FluMist®.

Approved therapeutics

Approved therapeutics for seasonal influenza A virus infections include the neuraminidase inhibitors oseltamivir
phosphate (Tamiflu®) and zanamivir (Relenza®) and the M2 ion channel blockers amantadine (Symmetrel®)
and rimantadine (Flumadine®).
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Table 2

Summary of current animal models available for studying benign disease associated with seasonal influenza
Virus

NIH-PA Author Manuscript

Disease Model

Animal Model

Influenza A strains
Aichi/2/68 (H3N2)
A/NIB/26/90M (H3N2)
A/NIB/23/89M (H1N1)
A/NIB/23/89-MA (mouse adapted

Mild Pathogenesis

Mouse
BALB/cJCitMoise (B/c)
A/SnJCitMoise
CBA/CaLacSto
C57BL/6LacSto

Gambaryan et al.,
2005

Influenza
A/Aichi/2/68 (H3N2)

Mild Pathogenesis

Ferret

Svitek et al., 2008

Influenza A/Port/Chalmers/173 (rat
adapted after 11 passages in rats

Mild Pathogenesis

Rat (Rattus) Brown Norway
Fischer-344 Sprague-Dawley

Daniels et al., 2003

Swine influenza A strains:X98 H3N2
A/SW/CO/23619/99 H3N2
A/SW/IA/00239/2004 rH1N1

Mild Pathogenesis

Pig

Mild Pathogenesis/Pneumonia

Pigtailed macaque

Influenza A H1N1
A/Texas/36/91

NIH-PA Author Manuscript
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Table 3

Summary of currently available animal models for studying severe seasonal influenza pneumonia
Virus

Animal Model

NIH-PA Author Manuscript

Influenza A H3N2 strains

Mouse (BALB/c)

References

Reviewed by Sidwell and Smee, 2000

A/Shangdong/09/93
A/Victoria/3/79
Influenza B strains
B/HongKong/5/72
B/Lee/40
B/Sichuan/379/99

BALB/c

Smee et al., 2006

Influenza A H1N1 strains

BALB/c

Smee et al., 2008

BALB/c

Smee et al., 2006

A/Charlottesville/31/95 (H1N1)

Ferret

Smee et al., 2008

A/USSR/90/77 (H1N1)

Ferret

Svitek et al., 2008

A/WSN/33 (H1N1) virus containing the HA gene of A/New
Caledonia/20/99
A/New Caledonia/20/99

Influenza A strains

NIH-PA Author Manuscript

A/Port Chalmers/1/73 (H3N2)

Influenza A H3N2

Cotton Rat

A/Wuhan/359/95
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Table 4

Summary of current animal models available for studying models of sepsis associated with influenza virus infections
Virus

NIH-PA Author Manuscript

Bacterial Infection

Disease Model

Animal Model

Influenza A H3N2
A/Scotland/20/74

Neisseria meningitidis

Sepsis model

Mouse (BALB/c)

Alonso, 2003

Influenza A H1N1
A/PR/8/34

Streptococcus pneumoniae

Sepsis model

Mouse (BALB/c)

Hayashi, 2006

Influenza A H1N1
A/PR/8/34

Streptococcus pneumoniae

Sepsis model

Mouse (BALB/c)

Smith, 2007

Influenza A H3N2
A/Sydney/5/97
A/Fujian/411/02
Influenza A H1N1
ATaiwan/1/86
Influenza B
B/Singapore/222/79

Streptococcus pneumoniae

Secondary bacterial infection
model

Ferret

Peltola, 2006

Staphylococcus aureus

Bacterial synergy model

Ferret

Braun, 2006

Influenza A H3N2
Wuhan/359/95

NIH-PA Author Manuscript
NIH-PA Author Manuscript
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Table 5

Summary of current animal models available for studying human disease caused by highly pathogenic H5N1 avian
viruses

NIH-PA Author Manuscript

Virus

A/duck/Tuva/01/06 (H5N1)

Disease Model

Animal Model

Interstitial pneumonia

Mouse (BALB/c)

References

Evenseeko et al., 2007

A/Vietnam/1203/2004
VN1204PB2-627Lys (mutant)

(BALB/c)

Hatta et al., 2007

A/Vietnam/1204/2004
VN1203PB2-627Glu (mutant)
A/chicken/Vietnam/NCVD5/2003
A/muscovy/duck/Vietnam/
NCVD18/2003
A/Vietnam/1194/04

(BALB/c)

A/Vietnam/1203/04 (VN1203)

Hatta and Kawaoka,
2005

A/Vietnam/1204/04 (VN1204)
A/duck/Vietnam/NCVD-5/03
A/duck/Vietnam/NCVD-18/03

NIH-PA Author Manuscript

A/duck/Vietnam/NCVD-25/03
A/chicken/Vietnam/NCVD-8/03
A/chicken/Vietnam/NCVD-15/03
A/chicken/Vietnam/NCVD-30/03
A/chicken/Yamaguchi/7/04
(BALB/c)

Isoda et al., 2006

(BALB/c)

Katz et al., 2000b

H5N1 viruses: A/Hong
Kong/481/97
A/HongKong/483/97
A/Hong Kong/485197
A/Hong Kong1486197
A/Hong Kong/507/97
H5N1 viruses: A/ck/HK/220/97

BALB/c

Dybing et al., 2000

A/ck/HK/728/97
A/HK/156/97

NIH-PA Author Manuscript

A/ck/Scotland/59
A/tk/England/91
A/HongKong/156/97

(BALB/c)

Influenza A H5N1

Pathogenesis/Pneumonia

Ferret

Gubareva et al., 1998a

Zitzow, 2002

A/Hong Kong/486/97
A/Hong Kong/483/97
Influenza B clinical isolate related to B/
Beijing/184/93 and B/Guangdong/8/93

Influenza A H5N1

Gubareva et al., 1998b

Pathogenesis/Pneumonia

Cat

Antiviral Res. Author manuscript; available in PMC 2010 May 1.

Rimmelzwaan et al.,
2006

Barnard
Virus
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Disease Model

Animal Model

Pathogenesis/Pneumonia

Cynomolgus macaque

References

A/Vietnam/1194/04

NIH-PA Author Manuscript

Influenza A H5N1
A/HongKong/156/97

Kuiken et al., 2003
Rimmelzwaan et al.,
2003

NIH-PA Author Manuscript
NIH-PA Author Manuscript
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Table 6

Summary of current animal models available for studying acute respiratory distress syndrome (ARDS) developing in
the setting of H5N1 avian influenza

NIH-PA Author Manuscript

Virus

Animal Model

Influenza A H5N1
A/Chicken/Hebei/108/2002
Influenza A H5N1
A/HongKong/156/97

Mouse (BALB/c)
Cynomolgus macaques

References
Xu, 2006
Kuiken et al., 2003
Rimmelzwaan et al., 2003

NIH-PA Author Manuscript
NIH-PA Author Manuscript
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Table 7

Summary of current animal models available for studying influenza virus-associated neurotropic disease
Virus

NIH-PA Author Manuscript

Influenza A H1N1
A/WSN/33
Influenza A H5N1
Recombinant R404BP
A/WSN/33 X A/Aichi/2/68
Influenza A H5N1
A/Hong Kong/483/97

Animal Model
Mouse (C57BL/6-BJ6)

References
Aronsson, 2003

Mouse (C57BL/6)

Mori, 2002

Mouse (BALB/cA Jcl)

Park, 2002

NIH-PA Author Manuscript
NIH-PA Author Manuscript
Antiviral Res. Author manuscript; available in PMC 2010 May 1.
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Table 8

Summary of current animal models available for studying drug-resistant influenza virus infections
Virus

NIH-PA Author Manuscript

Influenza A H4N2
A/turkey/Minnesota/833/80
Influenza A H1N1
NWS/G70C4-G

Animal Model

Drug

Mouse (BALB/CBYJ)

neuraminidase inhibitors

Mouse (C57BL6 X C57BL10) Ferret

zanamivir

NIH-PA Author Manuscript
NIH-PA Author Manuscript
Antiviral Res. Author manuscript; available in PMC 2010 May 1.
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Table 9

Summary of current animal models available for studying the immunocompromised host infected with influenza virus
Virus

NIH-PA Author Manuscript

Influenza A H1N1, NWS/33
Influenza A H2N2, Japan/
305/57

Disease Model

Animal Model

Cyclophosphamide immunosuppression
Immunocompromised mouse

Mouse(BALB/c) SCID Mouse

Immunocompromised mouse

SCID Mouse

NIH-PA Author Manuscript
NIH-PA Author Manuscript
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